glp-1-directed nmda receptor antagonism for obesity treatment A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings Frontiers | GLP−1 receptor agonists

For patients with severe obesity and metabolic disease, they save lives

Also relevant if you're considering GLP-1 therapy and want to establish a nutrient baseline first starting supplementation before or during early titration means you're replenishing from the start, not playing catch-up after depletion has already occurred

If the FDA approves GLP-1 weight loss patches in the future, patients using the patches may experience similar side effects as subcutaneous GLP-1 injections, including GI-related adverse effects

View CBS News In CBS News App Open Chrome Safari Continue

The cardiovascular benefits appear to precede any significant weight management and apply to people with or without type 2 diabetes

Diabetologia (2016) 59:111220